Ventricular assist devices.

Curr Opin Anaesthesiol

Department of Anaesthesiology, Université Catholique de Louvain, Belgium.

Published: February 2003

AI Article Synopsis

  • Recent advances in ventricular assist devices (VADs) include the development of fully implantable pumps and recognition of their new roles in treating end-stage heart failure as permanent support or recovery solutions.
  • Understanding how these devices alter heart function has improved, revealing that some patients may regain heart function post-support, but VAD therapy still entails significant complications like device failure and infections.
  • The debate continues on which VAD is best for specific cases, with early trials showing promise for new fully implantable devices regarding effectiveness and safety, though recovery as a clinical goal remains challenging.

Article Abstract

Purpose Of Review: Recent advances in technology as well as new indications for implantation have appeared in the field of ventricular assist devices. Progress has also been made in the understanding of the underlying mechanisms of myocardial recovery after ventricular assist device support.

Recent Findings: Technological progress includes the development of fully implantable pulsatile and continuous flow pumps, either axial flow or centrifugal, for left ventricular and total heart assistance. Among the new indications for ventricular assist device support, the most important is the use of the device as permanent treatment for end-stage cardiac failure patients. Increased knowledge has been acquired regarding the effects of mechanical assistance and of unloading of the heart on haemodynamics, as well as on the cellular, molecular and electrophysiological characteristics of the failing heart. All these findings suggest that depressed myocardial function can sometimes recover with ventricular assist device therapy. Ventricular assist device support, however, still carries a high rate of complications: the device itself can fail, bleeding and thromboembolism are common, immunity is disturbed and the incidence of infection remains high.

Summary: In patients with end-stage heart failure, ventricular assist devices can be used as a bridge to transplantation or to recovery, but they are now also considered as a long-term myocardial replacement therapy. Which device is the most appropriate for each indication, however, remains to be defined. Even if the underlying mechanisms of myocardial recovery are progressively clarified, the use of ventricular assist devices as a bridge to recovery still has limited clinical success. Clinical trials with the fully implantable devices are in their early stages, but these pumps appear promising in terms of efficacy, reliability and complication rate, as well as being easy to implant. Because more patients will benefit from ventricular assist device placement in the future, anaesthesiologists must be prepared to manage patients undergoing ventricular assist device placement or presenting for noncardiac surgery while under ventricular assist device support.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00001503-200302000-00006DOI Listing

Publication Analysis

Top Keywords

ventricular assist
44
assist device
28
assist devices
16
ventricular
12
device support
12
assist
10
device
10
underlying mechanisms
8
mechanisms myocardial
8
myocardial recovery
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!